Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748592 | 0.83 | CYP2D6 (0.42) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4748532 | 0.71 | HSD11B1 (0.39) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL2337932 | 0.70 | CYP2D6 (0.65) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL868771 | 0.70 | CYP2D6 (0.50) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL868770 | 0.70 | CYP2D6 (0.50) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2330314 | 0.69 | CYP2D6 (0.63) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL10568119 | 0.67 | CYP2D6 (0.55) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL28219815 | 0.67 | CYP2D6 (0.60) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL10819303 | 0.67 | CYP2D6 (0.60) | CYP2D6OPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL9009194 | 0.67 | CYP2D6 (0.55) | CYP2D6OPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP2D6 44/4885OPRL1 782/4885OPRM1 804/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | CYP2D6 44/4885OPRL1 782/4885OPRM1 804/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | CYP2D6 44/4885OPRL1 782/4885OPRM1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.